Having recently announced plans to launch a further four biosimilar products in the next four years, Fresenius Kabi has disclosed the latest on its bid to introduce pegfilgrastim, which has been hamstrung in the US by delayed inspections.
Fresenius Kabi expects to launch its pegfilgrastim biosimilar, Stimufend, in the EU “early next year” after revealing plans for a European Medicines Agency inspection by the end of the summer, although the US is proving a tricker prospect with COVID-19 related delays continuing to hinder US Food and Drug Administration inspections.
“We expect to launch Stimufend, first in a pre-filled syringe, followed by an on-body injector,” stated the Fresenius group’s president,...
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
